Compare American Superconductor Corporation (AMSC) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Superconductor Corporation vs DexCom, Inc. — how do they compare? American Superconductor Corporation trades at $32.69 (market cap $1.56B), while DexCom, Inc. trades at $90.15 (market cap $33.79B). The key difference: DexCom, Inc. is far larger — about 21.7× American Superconductor Corporation's market cap, and DexCom, Inc. is trading nearer its 52-week high, American Superconductor Corporation nearer its low. Which is the better fit depends on your goals.
| AMSC | DXCM | |
|---|---|---|
Market Cap | $1.56B | $33.79B |
Sector | Technology | Health |
52-Week High | $66.68 | $89.53 |
52-Week Low | $25.95 | $54.84 |
Enterprise Value | $1.42B | $33.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMSC trades at $33.19, up 7.1% today, showing strong momentum despite a bearish technical signal. The company reported record Q1 2026 revenue of $94.1 million, up 30% year-over-year, but missed earnings estimates due to margin pressure. Analyst consensus leans bullish with 53% buy ratings, while technical indicators show resistance at $34 and support at $30.
Outlook remains mixed with strong revenue growth and record backlog providing visibility, but margin compression and aggressive valuation pose risks. The stock offers growth potential in energy infrastructure markets, though investors should monitor execution on profitability targets amid increasing competition.
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
